Introduction

- GSK'254 is a next-generation HIV-1 maturation inhibitor with PK supporting once-daily (QD) therapy for HIV-1 treatment.
- In preclinical studies, minimal QT effects were observed in 1 dog administered a single dose of GSK'254 17 mg/kg up to a maximum concentration of 7960 ng/mL.
- In previous clinical studies, 1 healthy participant receiving GSK'254 200 mg reported an adverse event (AE) of isolated and limited palpitations without changes on electrocardiogram.
- In this 2-part, randomized, thorough QTc study, the effect of GSK'254 on cardiac repolarization was evaluated in healthy adults.

Methods

Part 1: Sentinel Cohort
- In part 1, healthy participants were randomized 3:1 to receive GSK'254 500 mg or placebo QD for 7 days to determine safety and PK of a 500-mg GSK'254 supratherapeutic dose.
- All doses were administered with a moderate-fat meal.

Part 2: Main QTc Study
- In part 2, healthy participants were randomized to 12 treatment sequences, each composed of 4 sequential 7-day treatment periods:
  - GSK'254 100 mg QD (potential therapeutic dose)
  - GSK'254 500 mg QD (supratherapeutic dose)
  - Placebo QD for 7 days
  - Placebo QD for 6 days and a single dose of metoflaxin 400 mg on Day 7
- Each treatment period was followed by a 7-day washout.
- All treatments were administered with a moderate-fat meal.

Assessments and Analyses
- In each treatment period, electrocardiograms were extracted in triplicate before dosing on Day 1 and pre-dose and through 24 hours post-dose on Day 7 of each treatment period.
- Assessments included heart rate, PR interval, QRS interval, and QT interval corrected using Fridericia’s formula (QTcF).
- Concentration–QTc (cQT) analyses modeled the relationship between individually observed GSK'254 plasma concentrations and placebo-adjusted change from baseline in QTcF (ΔΔQTcF).
- PK parameters were calculated by standard noncompartmental analysis.
- Safety assessments included monitoring of AEs.

Results

Participants
- Of 50 participants enrolled, 8/8 (100%) in part 1 and 40/42 (95%) in part 2 completed the study.
- 2 participants withdrew from the study in part 2 due to an AE (coronavirus infection) and pregnancy.
- In parts 1 and 2, 35 (70%) participants were male, 21 (42%) were White/Caucasian/European heritage, and 20 (40%) were Black/African American; mean age was 34 years.

Main QTc Study Findings
- On Day 7 in part 2, geometric mean (95% CI) GSK'254 maximum concentrations (Cmax) were observed 5 hours post-dose with GSK'254 dosing (100 mg: 830 [738, 934] ng/mL; 500 mg: 4260 [3750, 4840] ng/mL).
- Estimated population slope of the cQT model was 0.0025 ms per ng/mL (90% CI, 0.0020, 0.0030).
- Least squares (LS) mean ΔΔQTcF for GSK'254 100 mg followed the placebo pattern across time points, with a maximum LS mean ΔΔQTcF of 1.7 ms.
  - The upper bound of the 90% CI remained <10 ms through 24 hours post-dose.
  - Maximum LS mean ΔΔQTcF for GSK'254 500 mg exceeded the 10 ms threshold at 4.5 hours post-dose: 10.6 ms (90% CI, 7.75, 13.38).
- The upper bound of the 90% CI for ΔΔQTcF is expected to remain <10 ms at GSK'254 plasma concentrations <3070 ng/mL (Table 2).

Neither GSK'254 dose had clinically relevant effects on heart rate or cardiac conduction (ie, PR and QRS intervals).

Figure 1. Goodness-of-Fit Plot of the cQT Model

Figure 2. Model-Predicted Mean (95% CI) ΔΔQTcF at Geometric Mean Peak GSK'254 Concentrations Associated With 100- and 500-mg Doses

Conclusions
- No clinically relevant effects on QTc prolongation, heart rate, or cardiac conduction were seen in healthy participants at concentrations associated with projected therapeutic GSK'254 doses being evaluated in phase IIb studies (100-200 mg).
- These results support continued clinical development of GSK'254 for HIV-1 treatment.
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.